PUBLIC COMPANY
save$APREAprea Therapeutics, Inc.
$APREDoylestown, PA, USupdated 13d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Study of APR-1051 in Patients With Advanced Solid Tumors
- phase2Study Of ATRN-119 In Patients With Advanced Solid Tumors
- phase2Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
- phase3APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
- phase2p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
- phase1APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
- phase2p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
- phase2APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (4)
- Mar 12, 26grantHamill John P. · SrVP/CFO/Prin Fin & Acct Ofcr40,380 sh
- Mar 12, 26grantGilad Oren · President/CEO20,175 sh
- Mar 12, 26grantGilad Oren · President/CEO80,700 sh
- Mar 12, 26grantHamill John P. · SrVP/CFO/Prin Fin & Acct Ofcr10,095 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that